Immunovant, Inc. (IMVT) DCF Valuation

Immunovant, Inc. (IMVT) DCF Valuation
  • ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • ✓ Aucune Expertise N'Est Requise; Facile À Suivre

Immunovant, Inc. (IMVT) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Gain insight into your Immunovant, Inc. (IMVT) valuation analysis with our sophisticated DCF Calculator! This Excel template comes preloaded with real IMVT data, enabling you to adjust forecasts and assumptions to accurately determine the intrinsic value of Immunovant, Inc.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020		 AY2
2021		 AY3
2022		 AY4
2023		 AY5
2024		 FY1
2025		 FY2
2026		 FY3
2027		 FY4
2028		 FY5
2029
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -65.6 -106.8 -155.6 -209.6 -270.0 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .0 1.0 1.2 1.3 .2 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -65.7 -107.8 -156.8 -211.0 -270.2 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 100.6 400.1 493.8 376.5 635.4 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 3.0 1.1 12.9 .9 5.5
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable 1.2 2.4 18.6 1.4 7.2 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 -.2 -.3 -.2 -.4 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % -0.21911 -0.21911 -0.21911 -0.21911 -0.21911 -0.21911 -0.21911 -0.21911 -0.21911 -0.21911
EBITAT -65.8 -107.4 -156.7 -211.0 -270.8 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -67.6 -103.5 -151.3 -215.1 -269.7 -1.7 .0 .0 .0 .0
WACC, % 7.8 7.8 7.8 7.8 7.8 7.8 7.8 7.8 7.8 7.8
PV UFCF
SUM PV UFCF -1.5
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -2
Net Debt -635
Equity Value 634
Diluted Shares Outstanding, MM 138
Equity Value Per Share 4.59

What You Will Get

  • Real IMVT Financials: Access to historical and projected data for precise valuation.
  • Customizable Inputs: Adjust discount rates, tax implications, revenue forecasts, and capital investments.
  • Dynamic Calculations: Intrinsic value and NPV are automatically computed in real-time.
  • Scenario Analysis: Explore various scenarios to assess Immunovant’s future growth.
  • User-Friendly Design: Crafted for industry experts while remaining approachable for newcomers.

Key Features

  • Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Immunovant, Inc. (IMVT).
  • WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable inputs specific to Immunovant, Inc. (IMVT).
  • Customizable Forecast Assumptions: Easily alter growth rates, capital expenditures, and discount rates relevant to Immunovant, Inc. (IMVT).
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios for Immunovant, Inc. (IMVT).
  • Interactive Dashboard and Charts: Visual representations summarize key valuation metrics for straightforward analysis of Immunovant, Inc. (IMVT).

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review Immunovant, Inc.'s pre-filled financial data and forecasts.
  3. Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
  4. Step 4: Watch the DCF model update instantly as you tweak assumptions.
  5. Step 5: Analyze the outputs and use the results for investment decisions regarding Immunovant, Inc. (IMVT).

Why Choose Immunovant, Inc. (IMVT)?

  • Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
  • Strong Pipeline: Robust development pipeline focused on autoimmune diseases.
  • Expert Team: Led by industry veterans with extensive experience in biopharmaceuticals.
  • Commitment to Patients: Driven by a mission to improve the lives of those affected by chronic conditions.
  • Proven Track Record: Backed by successful clinical trials and positive outcomes.

Who Should Use This Product?

  • Investors: Accurately assess Immunovant, Inc.'s (IMVT) fair value prior to making investment choices.
  • CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Immunovant, Inc. (IMVT).
  • Consultants: Efficiently customize the template for valuation reports tailored to Immunovant, Inc. (IMVT) clients.
  • Entrepreneurs: Acquire insights into financial modeling practices employed by leading biopharmaceutical companies.
  • Educators: Implement it as a teaching resource to illustrate valuation techniques in the biotech sector.

What the Template Contains

  • Preloaded IMVT Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.